开源证券给予皓元医药买入评级，公司信息更新报告：前端业务高速增长驱动利润率提升，业绩超预期

七印授权

32OLRS3ZU5F5QT8B8IJWRVN95PL1S0B5CJBTI9M3WZLYKCN071

2024-08-29 15:09:18

article

3BFA80F750993E4B0C8AF039D2ED3A55E3A971869FE0B36835389C33F8C0C5B2

zh-CN

F1722BF5545DAA771A01AACBAB2DE8BF946DC900

17032654

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

a2d2fbcc6d8be1c5ccf9e6ed0b4dabeeb79f6afc208b8d20c1a4137d55ae961d15eacd448e4630463c0f33c9d57636339fd9a60c95dc940b481fcb82b01e642c1c

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_66d08f1e0219b2.72547719

原本认证

https://www.yuanben.io/article/187afee6-8d23-44f3-bce3-6718f0ebeab6

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}